A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction

ConclusionsEmpagliflozin added to SoC leads to health benefits for patients with HFrEF and is a cost-effective treatment option for payers in multiple European countries (UK, Spain, France).
Source: The European Journal of Health Economics - Category: Health Management Source Type: research